ASH 2014 Conference Review

Datamonitor Healthcare attended the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place between 6 December and 9 December 2014, in San Francisco, California.

Datamonitor Healthcare has identified the following key highlights from the meeting:

Data from Phase I and Phase II trials investigating several therapies based on chimeric antigen receptor T-cells (CAR-Ts) indicated promising efficacy for this class of therapies in the treatment of various B-cell malignancies, including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL).

Monoclonal antibodies (MAbs) continue to advance in pipeline development for multiple myeloma (MM).

Download whitepaper

Next steps

Request a Demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Datamonitor Healthcare has identified the following key highlights from the meeting:

Next steps

This is Contactus Section

Request a Demo

How can we help you?

Pharma Report Store

Pink Sheet

Trialtrove: gold standard clinical trials intelligence

Biomedtracker: see the drug development process through analysts’ eyes

ASH 2014 Conference Review

Datamonitor Healthcare has identified the following key highlights from the meeting:

Next steps

This is Contactus Section

Request a Demo

How can we help you?

Pharma Report Store

Related Products

Pink Sheet

Trialtrove: gold standard clinical trials intelligence

Biomedtracker: see the drug development process through analysts’ eyes